HRT Financial’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.12M Buy
+105,667
New +$3.41M 0.01% 1263
2025
Q4
Sell
-195,707
Closed -$5.14M 4115
2025
Q3
$5.14M Buy
195,707
+104,777
+115% +$3.13M 0.02% 663
2025
Q2
$2.41M Buy
90,930
+39,007
+75% +$1.03M 0.01% 837
2025
Q1
$1.25M Buy
+51,923
New +$1.64M 0.01% 1028
2024
Q3
Sell
-396,583
Closed -$21M 3193
2024
Q2
$21M Buy
+396,583
New +$26M 0.12% 123
2024
Q1
Sell
-124,971
Closed -$2.33M 3158
2023
Q4
$2.33M Buy
+124,971
New +$1.63M 0.02% 581
2023
Q2
Sell
-271,255
Closed -$4.52M 3343
2023
Q1
$4.52M Sell
271,255
-108,311
-29% -$1.12M 0.06% 275
2022
Q4
$3.57M Buy
+379,566
New +$1.69M 0.05% 365
2022
Q3
Sell
-176,166
Closed -$509K 3556
2022
Q2
$509K Sell
176,166
-57,900
-25% -$143K 0.01% 1462
2022
Q1
$702K Buy
234,066
+123,108
+111% +$442K 0.01% 1383
2021
Q4
$510K Buy
110,958
+40,203
+57% +$225K ﹤0.01% 1741
2021
Q3
$444K Buy
70,755
+50,271
+245% +$311K ﹤0.01% 2101
2021
Q2
$122K Buy
+20,484
New +$122K ﹤0.01% 2544
2021
Q1
Sell
-16,801
Closed -$94K 3186
2020
Q4
$94K Buy
+16,801
New +$102K ﹤0.01% 1643
2019
Q1
Sell
-45,631
Closed -$349K 807
2018
Q4
$349K Buy
+45,631
New +$546K 0.05% 306

Other funds holding VKTX

HRT Financial's VKTX Position: Q2 2026 in Review

HRT Financial opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 105,667 shares worth $4.12M. The stake represents 0.01% of the portfolio and ranks #1263 among its holdings. This is a return to the name: HRT Financial previously reported a position in VKTX as recently as Q3 2025.

HRT Financial first reported a position in VKTX in Q4 2018 and has held it in 15 quarters since. The position peaked at $21M in Q2 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • HRT Financial held 105,667 shares of Viking Therapeutics worth $4.12M as of Q2 2026.
  • Viking Therapeutics was a new HRT Financial position in Q2 2026.
  • Viking Therapeutics made up 0.01% of HRT Financial's portfolio in Q2 2026, its #1263 holding.
  • HRT Financial first reported a position in Viking Therapeutics in Q4 2018 and has held it in 15 quarters since.
  • HRT Financial's Viking Therapeutics position peaked at $21M in Q2 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.